jRCT2031230369Recruiting
Untitled Trial
Efficacy and safety of co administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor(NN9388 4896) (REIMAGINE2)
Novo Nordisk Pharma Ltd.Japan Registry Clinical Trial
VerifiedJapan Registry Clinical Trial
Study focus
- Disease/Condition
- Type 2 diabetes
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Novo Nordisk Pharma Ltd.
- Location
- Argentina;Australia;Brazil;Bulgaria;Canada;China;Colombia;Croatia;Czech;Denmark;Finland;Germany;Gree
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with multiple complications
Data source
- Registry
- Japan Registry Clinical Trial
- Trial ID
- jRCT2031230369
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for jRCT2031230369 through Pure Global AI's free database. This phase not specified trial is sponsored by Novo Nordisk Pharma Ltd. and is currently Recruiting. The study focuses on Type 2 diabetes.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.